A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy.
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Amlodipine/telmisartan (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 18 Jul 2016 Status changed from recruiting to completed.
- 17 Oct 2012 Planned number of patients changed from 900 to 600 as reported by ClinicalTrials.gov.
- 11 Mar 2011 Planned End Date changed from 1 Dec 2013 to 1 Aug 2016 as reported by ClinicalTrials.gov.